Innate Pharma Reports Positive Revenue Increase in FY 2023 Financial Results
Thursday, 21 March 2024, 09:21
Innate Pharma Reports FY 2023 Financial Results
Innate Pharma has published their financial results for the fiscal year 2023, highlighting important metrics such as revenue and GAAP EPS.
Revenue Growth
The company reported a revenue of €61.64M, reflecting a 6.9% year-over-year increase, indicating positive growth.
GAAP EPS Performance
The GAAP EPS stood at -€0.09, showcasing a continuation of certain financial challenges.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.